Lirafugratinib: A New Targeted Drug For Bile Duct Cancer
- The Food and Drug Administration (FDA) approved a new targeted therapy called Lyrfigtu (lirafugratinib) on September 23, 2026, for a specific type of bile duct cancer, known medically as cholangiocarcinoma.
- The drug was approved for patients with previously treated advanced disease whose tumors have a genetic change called a FGFR2 fusion or rearrangement.
- A lab test on the tumor can show whether that change is present. Patients should ask whether their tumor has had comprehensive molecular testing.
- In the study behind the approval, tumors shrank in nearly half of patients (46%).
- The drug is a pill taken once a day, and it can cause skin-, nail-, and mouth-related side effects.
On September 23, 2026, the Food and Drug Administration (FDA) approved a drug called lirafugratinib, sold under the brand name Lyrfigtu. It treats cholangiocarcinoma, a cancer that starts in the bile ducts, the thin tubes that carry digestive fluid from the liver. People often file bile duct cancer under the broad heading of “liver cancer.” The two are related, but they are not the same disease, and this approval is specifically for bile duct cancer.
Read MoreFGFR2 Fusion: What It Is & Why It Matters
Cancer cells sometimes carry specific errors in their genes that help them grow. One of these, found in some bile duct cancers, involves a gene called FGFR2. When part of that gene breaks and joins to another one, a change doctors call a fusion or rearrangement, it can act like a stuck accelerator, pushing the cancer to keep dividing.As Dr. Rubinson notes, about 10-15% of people with intrahepatic cholangiocarcinomas have this rearrangement.
The only way to know if a patient has it, and to determine if lirafugratinib might be an option, is to perform molecular testing, usually on a sample of the tumor and sometimes through a blood test.
Dr. Walid Chalhoub, a gastroenterologist at MedStar Georgetown University Hospital, stresses that patients should ask whether their tumor has had comprehensive molecular testing, including for FGFR2 fusions or rearrangements.
“This treatment is intended for tumors with that specific alteration. Without testing, an eligible patient could miss an important treatment option,” Dr. Chalhoub tells SurvivorNet. Broad testing, he adds, can also reveal other changes that help guide care.
What to Know About Bile Duct Cancer
What to Know About Lirafugratinib (Lyrfigtu)
Lirafugratinib (Lyrfigtu) is a targeted therapy. Instead of attacking fast-growing cells throughout the body the way standard chemotherapy does, it is built to block FGFR2 itself, the accelerator driving these tumors. It comes as a pill, taken once a day at home.
It is not the first drug to aim at FGFR2 in this cancer. Patients with this change now have “a third FGFR-targeted pill available when initial chemo-immunotherapy stops working,” Dr. Rubinson explains.
The drug’s approval rested on a study called REFOCUS, which enrolled 116 people with this cancer who had already been treated before.
The study showed:
- Tumors shrank meaningfully in 46% of patients.
- Among the people who responded, the benefit lasted a median of about 11.8 months.
“That is encouraging for a difficult-to-treat cancer,” Dr. Chalhoub says. “Although patients should discuss the potential benefits and side effects with their oncologist.”
Additionally, nearly all patients saw their cancer at least stop growing for a time, Dr. Rubinson says, and half went about 11 months or longer before the disease started progressing again.
However, everyone in this study received the drug, with no comparison group taking something else. So these numbers describe how people did on lirafugratinib, not how much longer it helped them live compared with another treatment.
The drugmaker also reported that patients lived a median of about 22.8 months.
A response is not a cure. For many people it means more time with the cancer under steadier control, which can matter a great deal.
Side Effects to Know About
No cancer drug is free of side effects. In the study, lirafugratinib (Lyrfigtu) was linked to skin-, nail-, and mouth-related effects. These included hand-foot skin reactions (redness, soreness, and peeling on the palms and soles), mouth sores, and changes to the nails.
The drug “requires close management of side effects, especially mouth sores and hand-foot skin reactions,” Dr. Rubinson says, and the hand-foot reactions “were severe in about one in three patients.”
Regular eye exams to check the retina are also part of treatment, because the drug can affect the back of the eye.
High blood phosphate, a common and bothersome problem with the older FGFR drugs, happened less often with lirafugratinib, thanks to its more selective design.
Because these side effects are common, doctors often lower the dose or pause treatment to keep them in check. In the study, most patients needed a dose adjustment at some point, and only a few had to stop the drug entirely.
The drug can also harm a developing pregnancy, so reliable birth control matters during treatment for anyone who could become pregnant or father a child.
What This Means For Patients
As Dr. Rubinson puts it, choosing which FGFR inhibitor to use “is a personalized conversation between a patient and their cancer care team.”
If this sounds like your situation, or your loved one’s, the next step is a conversation to weigh treatment options. A diagnosis of advanced bile duct cancer is frightening, and no single approval changes that overnight. But the options have been growing, slowly and steadily, and this is one more.
“The progressive change in options for patients with this disease has been remarkable,” Dr. Laleh Melstrom, a surgical oncologist who specializes in gastrointestinal (GI) cancers at City of Hope, tells SurvivorNet.
Those options, she notes, hinge on molecular profiling, because these cancers can carry a range of different genetic changes. This new agent gives patients “one more line of therapy and, most importantly, hope for more prolonged survival.”
The drug is expected to become available in the final months of 2026.
Questions To Ask Your Doctor
- Has my tumor been tested for an FGFR2 fusion or rearrangement? If not, can we do that testing now?
- If I have that change, is Lyrfigtu a reasonable option for me, and how does it compare with the other choices?
- How do the potential side effects compare?
- How will I be monitored during treatment?
Learn more about SurvivorNet's rigorous medical review process.
